G201702

G201702 is a long-acting recombinant human parathyroid hormone (PTH) analog currently under clinical development by Jiangsu Pacific Minoke Biopharmaceutical. It is primarily being investigated for the treatment of postmenopausal osteoporosis. As an agonist of the parathyroid hormone receptor 1 (PTH1R), G201702 mimics the anabolic actions of endogenous PTH, stimulating osteoblast differentiation and activity to increase bone formation and bone mineral density. The long-acting nature of the molecule is intended to reduce the frequency of administration compared to daily teriparatide injections, potentially improving patient adherence and therapeutic outcomes in chronic bone loss conditions.